IFNG and neoplasm: Once internalized into tumor cells, Rux can be released inside the tumor cells to inactivate the IFN‐γ‐JAK pathway and abolish PD‐L1 expression on the surface of tumor cells, thereby amplifying the immune response of prodrug nanovesicle‐based chemoimmunotherapy (Scheme1).